Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2010
11/24/2010CN101230043B 3-oxide-2-methylamide derivatives as well as preparation method and use thereof
11/24/2010CN101229183B Ribonucleic acid retrogradation snippet compound and applications thereof
11/24/2010CN101143890B New born calf brain active peptide, preparation method and application thereof in preparing anti-cancer medicament
11/24/2010CN101139393B KDR peptides and vaccines containing the same
11/24/2010CN101139347B Banisterine derivative compound and uses thereof
11/24/2010CN101121706B Coumarin derivatives, preparation method and use thereof
11/24/2010CN101120945B Application of 8-arylamine-3H-imidazole [4, 5-g] quinazoline derivatives
11/24/2010CN101074233B 4'-demethylpodoph-yllotoxin derivative, its production and use
11/24/2010CN101045715B Heterocycle inhibitor for glycogen synthase kinase gsk-3
11/23/2010US7838664 used as modulators or targets of developmental processes or disorders associated with developmental dysfunctions, such as cancer; tumor suppressors genes
11/23/2010US7838663 used as modulators or targets of developmental processes or disorders associated with developmental dysfunctions, such as cancer; tumor suppressors genes
11/23/2010US7838662 used as modulators or targets of developmental processes or disorders associated with developmental dysfunctions, such as cancer; tumor suppressors genes
11/23/2010US7838661 used as modulators or targets of developmental processes or disorders associated with developmental dysfunctions, such as cancer; tumor suppressors genes
11/23/2010US7838660 used as modulators or targets of developmental processes or disorders associated with developmental dysfunctions, such as cancer; tumor suppressors genes
11/23/2010US7838648 Purified SR-p70 protein
11/23/2010US7838644 oversulfation of epiK-N sulfate to obtain an epiK5-amine-O-oversulfate with very high sulfation degree which by subsequent N-sulfation provides new epiK5-N,O-oversulfate-derivatives; free of activity on the coagulation parameters and useful in the cosmetic or pharmaceutical field
11/23/2010US7838639 antibody that specifically binds to a human TNF Receptor in the BRAIN (TRAIN) polypeptide; useful in regulating cell differentiation, death, and survival
11/23/2010US7838637 Single-chain multiple antigen-binding molecule, its preparation and use
11/23/2010US7838560 Urokinase inhibitors, production and use thereof
11/23/2010US7838555 Useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and
11/23/2010US7838541 Methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
11/23/2010US7838530 Antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases;1-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}methyl)-L-prolinamide
11/23/2010US7838527 Methods of treating cancer and related methods
11/23/2010US7838520 Inhibitors of histone deacetylase
11/23/2010US7838519 Maytansinoid analogs as antitumor agents
11/23/2010US7838510 Biomaterials based on hyaluronic acid for the anti-angiogenic therapy in the treatment of tumors
11/23/2010US7838289 Assay utilizing multipotent adult stem cells
11/23/2010US7838275 Anti-HIV and anti-tumor peptides and fragments of lysozyme
11/23/2010US7838266 A purified pro-cytolytic peptide; used to treat localized and metastatic prostate cancer; administered intratumorally and/or intraprostatically
11/23/2010US7838043 administering scavenger of superoxide anion or nitric oxide comprising fine powder of platinum (colloid) which is prepared by metal salt reduction in presence of water-soluble polymer comprising polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid, cyclodextrin, amylopectin, and methylcellulose
11/23/2010US7838041 autologously transplanting hematopoietic progenitor cell population which has been treated with antibody (monoclonal, chimeric, or humanized; not conjugated to toxin or cytolytic agent); radiotherapy
11/23/2010US7838007 Methods for treating mammary gland disorders
11/23/2010US7837995 Anticancer agents; low dosage; side effect reduction
11/23/2010CA2503223C Meso-substituted porphyrins
11/23/2010CA2496295C Novels pyrazole compounds as transforming growth factor (tgf) inhibitors
11/23/2010CA2487489C Mitotic kinesin inhibitors
11/23/2010CA2478094C Methods of inducing terminal differentiation
11/23/2010CA2462085C Cytotoxic agents
11/23/2010CA2461068C Cell populations which co-express cd49c and cd90
11/23/2010CA2459380C Reverse hydroxamic acid derivatives
11/23/2010CA2440014C Beta-carboline derivatives and its pharmaceutical use against depression and anxiety
11/23/2010CA2434775C Compounds for use in the treatment of skin conditions
11/23/2010CA2423192C 1-azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors
11/23/2010CA2319836C Hydroxylation activated prodrugs
11/23/2010CA2315271C Platelet derived growth factor (pdgf) nucleic acid ligand complexes
11/23/2010CA2223989C Prodrugs of pharmaceuticals with improved bioavailability
11/21/2010CA2666446A1 Compositions for prostate and menstrual/menopausal related health
11/18/2010WO2010132882A2 Sublingual dexmedetomidine compositions and methods of use thereof
11/18/2010WO2010132879A2 Multicomponent degradable cationic polymers
11/18/2010WO2010132787A1 Methods of treating proliferative diseases
11/18/2010WO2010132742A1 Methods and compositions for modulating erbb2 activity
11/18/2010WO2010132684A2 Inhibitors of inv(16) leukemia
11/18/2010WO2010132664A1 Compositions and methods for drug delivery
11/18/2010WO2010132622A2 Anticd20-cpg conjugates and methods of treating b cell malignancies
11/18/2010WO2010132598A1 Heteroaryl compounds as pikk inhibitors
11/18/2010WO2010132525A1 Compounds containing acyclic n-o bonds for phototherapy
11/18/2010WO2010132520A1 Spiro 1,3,4-thiadiazoline derivatives as ksp inhibitors
11/18/2010WO2010132515A1 Compounds containing acyclic n-n bonds for phototherapy
11/18/2010WO2010132507A2 Methods for treatment of disease using an epimetabolic shifter (coenzyme q10)
11/18/2010WO2010132440A2 Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
11/18/2010WO2010132389A2 Methods for treating cancers and diseases associated with 4-1bb (cd137) expression
11/18/2010WO2010132110A1 Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
11/18/2010WO2010132047A1 Guanosine/gmp gels and uses thereof
11/18/2010WO2010132024A1 Lycopene and resveratrol compositions for nk cell activation resulting in anti-neoplastic effect
11/18/2010WO2010131992A1 Carbon-bearing nsp3 nanoparticle and a method for the production thereof
11/18/2010WO2010131769A1 Treatment of diffuse-type gastric cancers using s-1 and cisplatin
11/18/2010WO2010131738A1 Azetidine compound and medicinal use thereof
11/18/2010WO2010131733A1 Anti-axl antibody
11/18/2010WO2010131695A1 Modified double-stranded rna
11/18/2010WO2010131675A1 Polymer conjugate of bioactive substance having hydroxy group
11/18/2010WO2010131590A1 Diagnostic agent and therapeutic agent for tumors
11/18/2010WO2010131475A1 NOVEL STABLE CRYSTAL OF 1-(2'-CYANO-2'-DEOXY-β-D-ARABINOFURANOSYL)CYTOSINE MONOHYDROCHLORIDE
11/18/2010WO2010131460A1 Anti-tumor agent comprising tegafur-gimeracil-oteracil potassium combination drug and oxaliplatin
11/18/2010WO2010131452A1 Ttk peptides and vaccines including the same
11/18/2010WO2010131283A1 Peptide able to disrupt the protein complex between the his273 mutaded p53 protein and the oncosuppressive p73 protein in tumour cells and therapeutic uses thereof
11/18/2010WO2010131237A1 A process for producing a biologically active globular protein complex
11/18/2010WO2010131117A1 Use of inclusion bodies as therapeutic agents
11/18/2010WO2010131116A2 Use of lipid conjugates in the treatment of diseases associated with vasculature
11/18/2010WO2010131022A1 [1,2,4] triazolo [4,3-b] pyridazines as ligands of the androgen receptor
11/18/2010WO2010130934A2 2-cycloamino-5-(pyridin-4-yl)imidazo[2,1-b][1,3,4]thiadiazole derivatives, preparation thereof, and therapeutic use thereof
11/18/2010WO2010130900A2 Triaminopyrimidine derivatives as cdc25 phosphatase inhibitors
11/18/2010WO2010130779A2 COMBINATION OF A PBOSPBOINOSITKLE 3-KSπASE INHIBITOR AND AN ANTIDIABETIC COMPOUND
11/18/2010WO2010130758A1 New combination therapy in treatment of cancer and fibrotic diseases
11/18/2010WO2010130757A1 New combination therapy in treatment of oncological and fibrotic diseases
11/18/2010WO2010130751A1 Humanized axl antibodies
11/18/2010WO2010130677A1 Vhh antibody fragments that mimic her-2/neu
11/18/2010WO2010130468A1 New medicines for topic use based on sulfated hyaluronic acid as activating or inhibiting agent of the cytokine activity
11/18/2010WO2010130466A1 Sulphated hyaluronic acids as regulator agents of the cytokine activity
11/18/2010WO2010130224A1 Thiophene derivatives
11/18/2010WO2010130178A1 Acrylamide derivative and use thereof in manufacture of medicament
11/18/2010WO2010130053A1 COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGIC CANCERS TARGETING THE SIRPα - CD47 INTERACTION
11/18/2010WO2010111626A3 Poly (adp-ribose) polymerase (parp) inhibitors
11/18/2010WO2010108074A3 Inhibitors of pi3 kinase
11/18/2010WO2010106431A3 High affinity t-cell receptor-like ny-eso-1 peptide antibodies, methods, and uses thereof
11/18/2010WO2010101627A3 Methods and systems for treatment and/or diagnosis
11/18/2010WO2010088866A3 Novel saponin compounds, methods of preparation thereof, use thereof and pharmaceutical compositions
11/18/2010WO2010083104A3 Conjugates of noscapine and folic acid and their use in treating cancer
11/18/2010WO2010082789A3 Anticancer compositions comprising cedrol in nanoparticle form
11/18/2010WO2010077422A3 Formulations of single domain antigen binding molecules
11/18/2010WO2010076564A3 Isochromenones useful in the treatment of inflammation
1 ... 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 ... 2211